Stigmasterol reverses rituximab resistance in diffuse large B-cell lymphoma via the MAPK1 signaling pathway
{{output}}
Background: Rituximab (RIT) resistance significantly hampers the treatment efficacy in diffuse large B-cell lymphoma (DLBCL), leading to poor prognosis. We aim to investigate the potential of stigmasterol, a natural compound, to ... ...
